Used in cancer immunotherapy, particularly for targeting B7-H3 (CD276), a protein overexpressed in various solid tumors such as prostate, melanoma, lung, and head and neck cancers. It enables selective binding to tumor cells, facilitating antibody-dependent cellular cytotoxicity (ADCC) to enhance immune destruction of cancer cells. Investigated in clinical trials as a monotherapy and in combination with other agents like checkpoint inhibitors to improve anti-tumor responses. Also serves as a reference standard in the development of biosimilars and immunoassays for drug discovery and diagnostic applications.